Panel Introduction This summary is based on an AJMC Peer Exchange program titled “Advancing ALK+ NSCLC Care: Optimizing Treatment, Sequencing, and Long-Term Outcomes,” featuring the following ...

Ivonescimab combined with chemotherapy showed significant progression-free survival benefits in advanced squamous NSCLC patients, including both PD-L1-positive and PD-L1-negative populations. The ...

Deferring CNS-directed radiation therapy in EGFR-variant and ALK-positive NSCLC with brain metastases improves outcomes but increases treatment-related toxicity. Up-front stereotactic radiosurgery ...

Summit Therapeutics' ivonescimab shows promising results in China, outperforming Keytruda in PD-L1 positive advanced NSCLC, with potential $10 billion peak annual revenue. Fierce competition ...

Heterogeneous escalation of radiotherapy dose guided by imaging in locally advanced non–small cell lung cancer (NSCLC) does not increase early toxicity, a new trial found. “Patients with ...

The Food and Drug Administration has approved the first at-home test for cervical cancer screening, its maker Teal Health said on Friday, offering an alternative to Pap smears that need to be unde ...

Costco isn’t just a place to save — customers can apparently invest as well. A finance influencer who bought a small gold ingot at the big box retailer sold the nugget nearly a year later for ...

Bristol Myers Squibb (BMS) has secured another win for Opdivo (nivolumab), becoming the only FDA-approved PD-1 inhibitor for resectable non-small cell lung cancer NSCLC in both a neoadjuvant-only ...

Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen CE ...

In the Phase III HARMONi-6 trial, ivonescimab plus chemotherapy significantly outperformed tislelizumab plus chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer.